| Objective:Cognitive function and clinical symptoms were evaluated in the first-episode schizophrenia patients with risperidone combined with buspirone and risperidone alone.The aim was to investigate the efficacy of buspirone in cognitive function and the synergistic effects on mental symptomsin in first-episode schizophrenia patients,to promote the development of cognitive drugs for schizophrenia,to reduce cognitive impairment in patients with schizophrenia,and lay the foundation for the subsequent exploration of potential neurobiological studies of cognitive impairment in schizophrenia.Objects and methods:From May 2018 to February 2019,a total of 67 first-episode patients were enrolled in Xi'an Mental Health Center,the patients were randomly divided into risperidone with buspirone group of 35 patients(study group or buspirone group)and risperidone groupof 32 patients(control group).At baseline,8 weeks and 12 weeks,the cognitive function assessment was performed on the two groups of patients using the consensus version of the schizophrenia cognitive function test(the Measurement And Treatment Research to Improve Cognition In Schizophrenia Consensus Cognitive Battery,MCCB),the positive and negative symptom scales(Positive and Negative Symptoms Scale,PANSS)were used to evaluate the clinical symptoms of the two groups,using The Treatment Emergent Symptom Scale(TESS)assesses the side effects of the medication process.Blood routine,biochemical and electrocardiographic examinations were performed in the study to compare changes in cognitive function and symptoms before and after treatment.Finally,the study provides a theory for the clinical use of cognitive function in patients with schizophrenia by comparing changes in cognitive function and symptoms before and after treatment,and the correlation between symptoms and cognitive domains,and monitoring side effects during medication.Based on,thereby improving cognitive impairment and promoting disease and social function recovery.Result:1.The total scores of buspirone group,information processing speed,working memory,language learning,visual learning,reasoning and problem solving increased with the treatment time(p<0.05),while the control group only have cognition total score and information processing speed were higher than baseline at 8 weeks and 12 weeks(p<0.05),and there was no significant difference between 12 weeks and 8 weeks(p>0.05),and between the two groups at baseline,8 weeks,and 12 weeks,there was no significant difference(p>0.05);attention scores in the buspirone group increased with the treatmenttime(p<0.05),but there was no significant difference between the control group and the control group at 8 weeks and 12 weeks(p>0.05).The score of the buspirone group was higher than that of the control group at 8 weeks and 12 weeks(p<0.05).There was no significant difference between the two groups in the social cognition between the 8th week and the 12 th week(p>0.05),and there was no statistical difference between the two groups.Academic significance(p>0.05).2.The total scores of PANSS and negative symptoms in the buspirone group decreased with the prolongation of treatment time(p<0.05),and the control group decreased from baseline at 8 weeks and 12 weeks(p<0.05).There was no significant difference at 8 weeks(p>0.05),and there was no significant difference between the two groups at baseline,8 weeks,and 12 weeks(p>0.05).The general psychiatric symptoms in the buspirone group were lower than baseline at 8 weeks and 12 weeks.(p<0.05),there was no significant difference between the 12 th week and the 8th week(p>0.05),and the control group continued to decrease with the extension of the treatment time of 8 weeks and 12 weeks(p<0.05),but at the baseline between the two groups.There was no significant difference at 8 weeks and 12 weeks(p>0.05).The positive symptom scores of buspirone group decreased with the prolongation of treatment time at 8 weeks and 12weeks(p<0.05).The control group was 8 weeks,12 weeks.Weekly reduction compared with baseline(p<0.05),no significant difference between 12 weeks and 8 weeks(p>0.05),and there was no significant difference between the two groups at baseline,there was significant difference at 8 weeks and 12 weeks(p<0.05).The buspirone group score was lower than the control group.3.There was no correlation between attention and improvement in positive symptoms at 8 weeks and 12 weeks of treatment.4.There was no obvious side effect of the drug in the buspirone group and the control group after 12 weeks of treatment.Conclusion:Buspirone combined with risperidone improves attention in patients with first-episode schizophrenia compared with risperidone alone;buspirone combined with risperidone improves priming schizophrenic patients more than risperidone alone Symptoms;buspirone combined with risperidone had no correlation with improvement in attention deficit in patients with first-episode schizophrenia;buspirone combined with risperidone(40mg/day)had relatively small side effects.Relatively safe and effective. |
PDF Full Text Request